JP2007513610A5 - - Google Patents

Download PDF

Info

Publication number
JP2007513610A5
JP2007513610A5 JP2006540415A JP2006540415A JP2007513610A5 JP 2007513610 A5 JP2007513610 A5 JP 2007513610A5 JP 2006540415 A JP2006540415 A JP 2006540415A JP 2006540415 A JP2006540415 A JP 2006540415A JP 2007513610 A5 JP2007513610 A5 JP 2007513610A5
Authority
JP
Japan
Prior art keywords
cells
effective
human gamma
chimerized
thp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006540415A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007513610A (ja
Filing date
Publication date
Priority claimed from EP03292873A external-priority patent/EP1532984A1/en
Application filed filed Critical
Publication of JP2007513610A publication Critical patent/JP2007513610A/ja
Publication of JP2007513610A5 publication Critical patent/JP2007513610A5/ja
Pending legal-status Critical Current

Links

JP2006540415A 2003-11-19 2004-11-19 キメラ抗ｃｄ４４抗体およびそれらの使用 Pending JP2007513610A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03292873A EP1532984A1 (en) 2003-11-19 2003-11-19 Use of anti CD44 antibodies for eradicating stem cells in acute myeloid leukemia
PCT/EP2004/014157 WO2005049082A2 (en) 2003-11-19 2004-11-19 Chimeric anti cd44 antibodies and their use for treating acute myeloid leukemia

Publications (2)

Publication Number Publication Date
JP2007513610A JP2007513610A (ja) 2007-05-31
JP2007513610A5 true JP2007513610A5 (enExample) 2007-11-22

Family

ID=34429570

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006540415A Pending JP2007513610A (ja) 2003-11-19 2004-11-19 キメラ抗ｃｄ４４抗体およびそれらの使用

Country Status (10)

Country Link
US (4) US20050147606A1 (enExample)
EP (3) EP1532984A1 (enExample)
JP (1) JP2007513610A (enExample)
KR (1) KR20060126659A (enExample)
CN (1) CN1898268A (enExample)
AT (1) ATE480565T1 (enExample)
AU (1) AU2004290918B2 (enExample)
CA (2) CA2484459A1 (enExample)
DE (1) DE602004029078D1 (enExample)
WO (1) WO2005049082A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071072B2 (en) * 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
EP2783700A1 (en) * 2006-09-07 2014-10-01 Stemline Therapeutics, Inc. Cancer stem cell-targeted cancer therapy
US20080118432A1 (en) * 2006-09-07 2008-05-22 Ivan Bergstein Monitoring cancer stem cells
UY30776A1 (es) * 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
EP2009028A1 (en) * 2007-06-27 2008-12-31 Monoclonal Antibodies Therapeutics Combination of a conventional anti-cancer treatment with anti-CD44 antibody administration for treating solid tumors
CN101368173B (zh) * 2008-04-09 2011-12-28 协和干细胞基因工程有限公司 抗人cd44的工程抗体、载体、试剂盒及其用途
AU2010221168A1 (en) * 2009-03-06 2011-10-06 Angstrom Pharmaceuticals, Inc. Compositions and methods for modulation of cell migration
SI2531527T1 (sl) * 2010-02-04 2014-07-31 F. Hoffmann-La Roche Ag Monoklonsko protitelo proti CD44 za uporabo pri zdravljenju skvamoznoceličnega karcinoma glave in vratu
AU2011317211B2 (en) * 2010-10-22 2015-04-16 Dana-Farber Cancer Institute, Inc. Discovery of regulatory T cells programmed to suppress an immune response
BR112014010009A2 (pt) * 2011-10-26 2017-04-25 Univ California "anticorpo que se liga a cd44, seus métodos de produção e usos no tratamento ou prevenção de malignidade hematológica ou leucemia linfocítica crônica, método de alvejar anticorpo, kit de detecção, bem como composição farmacêutica, molécula de ácido nucleico e vetor de expressão"
US20150151004A1 (en) * 2013-06-14 2015-06-04 The University Of Kansas Methods and compositions of modulating tumor initiating cells and the use thereof
NL2011904C2 (en) * 2013-12-06 2015-06-09 Stichting Vu Vumc Leukemic stem cell markers.
CA3078963A1 (en) * 2017-10-25 2019-05-02 Actinium Pharmaceuticals, Inc. Anti-cd45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies
WO2021160269A1 (en) * 2020-02-13 2021-08-19 UCB Biopharma SRL Anti cd44-ctla4 bispecific antibodies
US12673992B2 (en) 2020-02-13 2026-07-07 UCB Biopharma SRL Bispecific antibodies against CD9 and CD7
CN113552363B (zh) * 2020-04-03 2024-03-08 中国科学院广州生物医药与健康研究院 Cd44作为造血干/祖细胞的标志物及其应用
JP7869149B2 (ja) 2020-05-19 2026-06-02 アンスティテュ・クリー サイトカイン放出症候群の診断及び処置の方法
JP2024518200A (ja) 2021-05-18 2024-04-30 ヤンセン バイオテツク，インコーポレーテツド Ｔ細胞リダイレクト治療薬及び抗ｃｄ４４治療薬を含む組成物
CN114316049B (zh) * 2021-12-24 2022-08-09 北京市神经外科研究所 Cd44抗体、嵌合抗原受体及其应用
CN114213538B (zh) * 2021-12-24 2022-07-08 北京市神经外科研究所 Cd44抗体、嵌合抗原受体及其应用
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024170543A1 (en) 2023-02-14 2024-08-22 Institut National de la Santé et de la Recherche Médicale Anti-cd44 antibodies and uses thereof
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5543594A (en) * 1992-10-30 1994-05-24 Duke University An adhesion molecule
FR2715664B1 (fr) 1994-01-31 1996-04-12 Proteine Performance Sa Baculovirus recombinant et son utilisation pour la production d'anticorps monoclonaux.
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
EP0826696B1 (de) * 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
JPH10301492A (ja) * 1997-04-23 1998-11-13 Sony Corp 暗号化装置および方法、復号装置および方法、並びに情報処理装置および方法
ES2301525T3 (es) * 2000-01-21 2008-07-01 Sony Corporation Sistema de autentificacion de datos.
TW538636B (en) * 2000-09-01 2003-06-21 Matsushita Electric Industrial Co Ltd Reproduction equipment, reproduction equipment specifying equipment, reproduction equipment specifying system and methods and recording media for said equipment and system
US6972324B2 (en) * 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
DK1401869T3 (da) * 2001-06-01 2008-04-28 Biogen Idec Inc Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1

Similar Documents

Publication Publication Date Title
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
HK1250238A1 (zh) 抗angptl8抗体及其用途
WO2016201450A3 (en) Cancer treatment and diagnosis
CY1120434T1 (el) Πρωτεϊνες προσδεσης il-1
EA202190248A1 (ru) Димерные иммуномодулирующие соединения против механизмов на основе цереблона
BR112012013038A2 (pt) mutantes fc de anticorpo com funções efetoras ablacionadas
EP1990374A4 (en) C.I. PIGMENT RED 57: 1 AND METHOD OF MANUFACTURING THEREOF
EA201891435A1 (ru) Гуманизированные моноклональные антитела, моноклональные антитела мыши или химерные моноклональные антитела против cd47
EP4628094A3 (en) BAFF-R ANTIBODIES AND THEIR USES
CY1121335T1 (el) Anti-cxcr3 αντισωματα
TW200732347A (en) VEGF analogs and methods of use
CY1113848T1 (el) Μικροοργανισμοι για τη βελτιωση της υγειας ατομων με διαταραχες που σχετιζονται με την προσληψη γλουτενης
EP2860192A3 (en) Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
EA201101520A1 (ru) Способы диагностики онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
NO20091413L (no) WNT-antagonister og deres anvendelse i diagnostiseringen og behandlingen av WNT-medierte forstyrrelser
EA202090031A2 (ru) Человеческие антитела против gfr3 и способы их применения
UA105760C2 (uk) Антитіло проти bst2
EP4524569A3 (en) Methods, compositions and devices for treating cancer with illudofulvenes
NO20073175L (no) Antigene epitoper av interleukin-21, relaterte antistoffer og anvendelse derav innen det medisinske omradet
WO2016130572A3 (en) Methods of determining levels of exposure to radiation and uses thereof
DE60217698D1 (de) Behandlung chronischer gelenkentzündung unter verwendung eines antikörpers gegen das cd3 antigenkomplex
CY1118918T1 (el) Παραγοντες εξαλειψης κυτταρων β, οπως αντισωματα enanti-cd20 ή θραυσματα αυτων για την αντιμετωπιση συνδρομου χρονιας κοπωσης
WO2007065010A3 (en) Anti-angiogenesis compounds
EA201001266A1 (ru) Эффективные противоопухолевые парамиксовирусы
EA202092156A1 (ru) Модифицированные олигонуклеотиды и способы применения в лечении таупатий